Intercept Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Intercept Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Intercept Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Intercept Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Intercept Pharmaceuticals Inc (Intercept), a subsidiary of Alfasigma SpA, is a biopharmaceutical company that discovers, develops and commercializes novel drugs for the treatment of progressive non-viral liver diseases with high unmet medical need.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Intercept R&D's arm focuses on developing novel therapeutic applications for multiple liver diseases, particularly those with high unmet needs. The company is leveraging its extensive research background in bile acids and FXR agonism to expand its pipeline, aiming to deliver effective treatments for serious liver diseases. A key project is the Phase 2a FRESH study, which evaluates the next-generation FXR agonist, INT-787, for severe alcohol-associated hepatitis (sAH). The R&D unit of Intercept is responsible for managing the company's research and development activities, focusing on exploring the potential of FXR agonists in diseases involving the liver and gut.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer